Climatic Chamber Configurator
Discover the Climatic Chamber Configurator
Our guide to choosing the climate chamber best suited to your needs.
The ICH Q1A stability test is the fundamental procedure that every pharmaceutical company must follow to determine the shelf life of their products. Defined by the ICH Q1A(R2) of the International Council for Harmonization, this standard establishes the temperature and humidity conditions to which drugs, active ingredients, and finished products must be subjected to verify their stability over time. The test is performed in ICH stability chambers, which maintain these conditions constant for the entire duration of the study.
In this guide, we take a detailed look at testing conditions, ICH climate zones, the difference between long-term and accelerated studies, and the role of climate chambers in conducting these tests.
The ICH Q1A stability study chamber
Long-term, intermediate and accelerated conditions (25°C/60% RH, 30°C/65% RH, 30°C/75% RH, 40°C/75% RH) are all within the working range of our ICH test chambers, which regulate humidity from 10 to 80% RH between +10°C and +60°C. The 21 CFR Part 11 option is available for data management.
Configure your ICH chamber and ask for pricing. Technical data sheets (PDF).
What is the ICH Guideline Q1A(R2)
ICH Q1A(R2) — “Stability Testing of New Drug Substances and Products” — is the global reference document for pharmaceutical stability testing. Published by the ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use), it defines:
- Environmental conditions ( temperature and humidity) for each type of study
- The minimum duration of stability studies
- Sampling frequencies during the test period
- Criteria for determining shelf-life and storage conditions
The standard is recognized by the FDA (USA), EMA (Europe) and PMDA (Japan) and is a mandatory requirement for the registration of new drugs in all regulated markets.
ICH Q1A Test Conditions
ICH Q1A defines three main types of studies, each with specific environmental conditions that must be precisely maintained within dedicated climate chambers.
Long-Term Study
Simulates real-world drug storage conditions. The minimum shelf life is 12 months at the time of regulatory submission, continuing until the entire proposed shelf life is covered. Sampling occurs at 0, 3, 6, 9, and 12 months, and then every 6 months.
Intermediate Study (Intermediate)
Required when significant changes are observed during the accelerated study. Conditions: 30°C / 65% RH for 12 months.
Accelerated Study
Predicts long-term stability in short times by subjecting the drug to controlled stress conditions. Minimum duration: 6 months with sampling at 0, 3, and 6 months.
| Type of study | Temperature | Humidity RH | Minimum duration | ICH Zone |
|---|---|---|---|---|
| Long-term | 25°C ±2°C | 60% ±5% | 12 months | I-II |
| Long-term | 30°C ±2°C | 65% ±5% | 12 months | III-IVa |
| Long-term | 30°C ±2°C | 75% ±5% | 12 months | IVb |
| Intermediate | 30°C ±2°C | 65% ±5% | 6 months | I-II |
| Accelerated | 40°C ±2°C | 75% ±5% | 6 months | All |
ICH Climate Zones: Which One Applies?
Long-term testing conditions depend on the climate zone in which the drug will be distributed. The ICH defines 4 main zones:
- Zone I — Temperate climate (Northern Europe, Canada): 21°C / 45% RH
- Zone II — Subtropical and Mediterranean climate (Southern Europe, USA, Japan): 25°C / 60% RH
- Zone III — Hot and dry climate (Middle East, North Africa): 30°C / 35% RH
- Zone IVa — Hot and humid climate (Brazil, Southeast Asia): 30°C / 65% RH
- Zone IVb — Hot and very humid climate (tropical): 30°C / 75% RH
For European markets (Zone II), standard conditions are 25°C / 60% RH. For global distribution, many pharmaceutical companies choose to test directly at 30°C / 75% RH (Zone IVb) to cover all markets in a single study.
ICH Q1B: The Photostability Test
Complementary to Q1A, ICH Q1B defines the requirements for photostability testing: verification that the drug does not degrade when exposed to light. The test involves exposure to:
- Visible light: minimum 1.2 million lux·hour
- UV radiation: minimum 200 W h/m²
These tests require controlled lighting chambers equipped with specific lamps such as the ICHlamp FDM
The Role of Environmental Chambers in ICH Testing
ICH stability testing requires climate chambers capable of maintaining extremely stable environmental conditions for months or years. The key requirements are:
- Accuracy: tolerance of ±2°C on temperature and ±5% on relative humidity
- Stability: no significant deviations throughout the duration of the study (up to 36 months)
- Uniformity: homogeneous distribution of temperature and humidity throughout the useful volume
- Data recording: continuous monitoring with document log for IQ/OQ/PQ qualification
- Alarms: notifications in case of deviations from the set parameters
FDM’s ICH Q1A/B test chamber is specifically designed to meet these requirements, with temperature ranges from -25°C to +70°C, controlled humidity 10-80% RH between +10°C and +60°C, and volumes from 140 to 2,300 liters.
Who Needs ICH Stability Tests?
ICH Q1A testing isn't just for large pharmaceutical companies. It's mandatory for:
- Pharmaceutical manufacturers: for the registration of new drugs with the FDA, EMA, PMDA
- CDMOs (Contract Development and Manufacturing Organizations): which perform stability studies on behalf of third parties
- Quality control laboratories: for checking production batches
- Nutraceutical and cosmetic companies: adopting ICH guidelines as best practice
- R&D departments: for the development of new formulations and packaging
The medical device industry uses ICH-derived stability protocols to validate the shelf life of its products.
The FDM Solution
FDM Environment Makers has been manufacturing ICH Q1A and Q1B test chambers since 1949. FDM chambers for the pharmaceutical industry are designed to ensure compliance with ICH guidelines with maximum reliability over time.
Each chamber can be supplied with complete documentation for IQ/OQ/PQ qualification and with the FDM Start service for installation and commissioning.
Discover the ICH Q1A/B FDM Test Chamber or contact us for technical advice on your pharmaceutical stability project.
Frequently Asked Questions about ICH Q1A Tests
How long does an ICH Q1A stability test take?
The accelerated study lasts a minimum of 6 months (40°C / 75% RH). The long-term study requires at least 12 months at the time of regulatory submission, but typically continues for 24–36 months to support the proposed shelf life.
What is the difference between ICH Q1A and ICH Q1B?
ICH Q1A concerns stability under controlled temperature and humidity conditions. ICH Q1B concerns photostability, or the drug's resistance to exposure to light. Both are required for a complete registration dossier.
What type of climate chamber is needed for ICH testing?
A climate chamber with temperature and humidity control capable of maintaining stable conditions for months is required. For the ICH Q1B, a chamber with controlled lighting. The required accuracy is ±2°C and ±5% RH.
Learn more: Also read our guide on the IQ/OQ/PQ Qualification of Stability Chambers and the guide to Pharmaceutical Climatic Chambers.
Speak directly with our engineers
Do you need to pass a regulatory test or are you looking for a chamber designed to your test protocol? Tell us your needs: the FDM technical team will respond to you, without intermediaries.
